Navigation Links
Researchers Identify a New Genetic Risk Factor for Severe Psychiatric Illness
Date:11/19/2013

Manhasset, NY (PRWEB) November 19, 2013

Investigators at The Feinstein Institute for Medical Research have discovered a new genetic risk factor for schizophrenia and bipolar disorder called NDST3. The findings are published online today in Nature Communications.

The study by a team lead by Todd Lencz, PhD, associate investigator at the Zucker Hillside Hospital Department of Psychiatry Research and Feinstein Institute, studied more than 25,000 individuals. In collaboration with Ariel Darvasi, PhD, of the Hebrew University of Jerusalem, Dr. Lencz has been working with a set of DNA samples from patients with schizophrenia and healthy volunteers drawn from the Ashkenazi Jewish population. The Ashkenazi Jewish population represents a unique population for study because of its short (less than 1,000-year) history and limited population. This history results in a more uniform genetic background in which to identify disease-related variants.

“This study again demonstrates the value of our Ashkenazi cohort,” said Dr. Lencz. “It is notable that the genetic variant was replicated in samples of various ethnicities from all around the world, but the effects were strongest in the Ashkenazi cohort, presumably due to their unique genetic history.”

Dr. Lencz’s team reported that the genetic variant, which changes a single “letter” of the DNA code, alters the expression of the gene NDST3. This gene is critical to neurodevelopmental processes such as axon formation and synaptic function. These findings shed new light on the genetic architecture and potential therapeutic targets for the treatment of psychiatric disease.

Schizophrenia and bipolar disorder are severe psychiatric disorders that affect 1-4 percent of the global population. Studies have shown that the two disorders are likely to have a large overlap in genetic risk factors, but only a small portion of this genetic risk has been identified.

This work was supported by a grant from the National Institute of Mental Health (NIMH), funded as part of the American Recovery and Reinvestment Act of 2009 (also known as the economic stimulus plan). More recently, the work by Drs. Lencz and Darvasi with the Ashkenazi schizophrenia cohort has received an additional $3 million from the NIMH, as well as grants from the Brain & Behavior Foundation and the Binational Science Foundation.

Dr. Lencz is also the co-leader of The Ashkenazi Genomics Consortium, a collaborative effort involving more than a dozen investigators from leading institutions (including Columbia University, Mt. Sinai School of Medicine, Albert Einstein College of Medicine and MIT), using similar strategies to understand the genetic basis of diseases including cancer, diabetes, and Parkinson’s.

About The Feinstein Institute for Medical Research

Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit http://www.FeinsteinInstitute.org.

# # #

Read the full story at http://www.prweb.com/releases/2013/11/prweb11345456.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Mobile Reporting Platform from OneWhitePixel Links Scientific Researchers With Field Reporters
2. Researchers find protein that regulates the burning of body fat
3. Johns Hopkins heart researchers develop formula to better calculate bad cholesterol in patients
4. U of M researchers find HIV protein may impact neurocognitive impairment in infected patients
5. Nanotech researchers 2-step method shows promise in fighting pancreatic cancer
6. Get Out and Play! Radio Flyer is Searching for Innovative New Ride-On Toys for Kids to Inspire Outdoor Play as Researchers Recommend Limiting Kids' Screen Time
7. McMaster researchers test bandaging for swollen arm
8. Mayo Clinic: Researchers to study bodys defense system to find new treatments for Alzheimers
9. Researchers call for health-care changes to help adults with developmental disabilities
10. Researchers discover that the body clock may influence morning peak in adverse cardiovascular events
11. Researchers identify a histone demethylase associated with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... New York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are ... every 3 kids do not brush their teeth the minimum two times a day that ... teeth; with students missing 51 million hours of school and adults missing 164 million hours ...
(Date:3/23/2017)... Los Angeles, CA (PRWEB) , ... March 23, ... ... Series A funding investment in Los Angeles based healthcare technology company California Healthcom ... group’s portfolio into the US, and healthcare arena. With headquarters in California, CHG ...
(Date:3/23/2017)... ... 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) from nearly ... in crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle ... , “We’re excited to be operating on U.S. shores, where most of our initial ...
(Date:3/23/2017)... ... 23, 2017 , ... According to the National Sleep Foundation , poor ... the only cause of the sunken-eye look, which can include dark circles or bags ... poor health are likely due to genetics, dehydration, allergies, and losing fat beneath the ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance ... Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , ... only to the association, but also to the Health Care Quality and Patient Safety ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, 2017 /PRNewswire/ ... "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... announced that data from its successful Phase 2a study ... treatment for localized prostate cancer, will be presented as ... nd Annual European Association of Urology in ...
(Date:3/23/2017)... 2017  Ethicon* today announced the completion of ... held medical device company that manufactures and markets ... treatment of Gastroesophageal Reflux Disease (GERD). This acquisition ... portfolio of minimally invasive options for patients suffering ... of the transaction have not been disclosed. ...
(Date:3/23/2017)... LITTLE SILVER, N.J. , March 23, 2017 ... device company, today announced that it has kicked ... in-growth into their 3D printed bone segments. ... of Engineering, "Our unique variable honeycomb lattice structures ... bone in-growth as compared to current allograft wedges ...
Breaking Medicine Technology: